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ABSTRACT
A full understanding of an enzyme’s catalytic mechanism and a crystal structure
representative of its in vivo form are powerful tools in computational drug screening and
design. In the case of aspartate transcarbamoylase (ATCase), an allosteric enzyme, the
mechanism and allosteric transition are still being explored. The crystallization of the
ATCase mutant Asp236 to alanine, a T-state destabilized mutant, in the presence of
phosphonoacetamide (PAM) by microdialysis was successful at pH 5.7. The enzyme
crystallized in the R-state in the presence of only one substrate analogue. Globally the
enzyme had converted to R, but the active site domains are more open than previously
observed. Due to the ordered nature of the reaction, the R-state active site exists with a
variety of small molecules bound at different times through out the course of the reaction.
This structure shows an R-state active site with only one substrate analogue bound, and
may therefore represent the R active site after catalysis has occurred and the active site is
binding new substrates to perform its reaction again. Docking studies of small molecules
can be conducted using this more open, emptier active site as it may be more
representative of an in vivo conformation of the enzyme just before catalysis.
Additionally, Arg296, previously unobserved as part of the active site, makes a hydrogen
bonding interaction with the PAM molecule. The role of this residue will require further
investigation.
ii
Dedication
To my parents who were always proud of, but never surprised by my accomplishments.
They take it all in stride, and despite there being three of us, never get winded,
To my sister, my best friend, for forging ahead on difficult paths and then turning around
to take my hand that I might not stumble,
And finally, to my brother, who reminds me that there is more out there than doing my
homework and that maybe I should go outside and play.
iii
Acknowledgements
My first thanks must go to Dr. Kantrowitz for his bravery in taking me on, and his
unwavering support that has helped me to grow as a researcher and a student. Without
him, none of this would have come together. His lab has been a home that will never be
forgotten. That said, my group must also be recognized. Most especially, I would like to
express my gratitude to Jim Cardia; graduate student, mentor, and friend. You who
struggled alongside me, Robin Skory and Liz O’Day, know that you are especially
appreciated. I also would like to extend thanks to Kim Stieglitz who spent patient hours
refining the crystal data, teaching me to use numerous programs and designing figures.
My larger support system cannot be neglected. For four years the Sailing Team has
offered refuge and taught me lessons that cannot be learned in the classroom or even in
the lab, and for these things I am forever grateful. There have also been those along the
way who made the journey this past year easier in a hundred small, unnamable ways; so a
thank you Steph, Rob, and Maciej for everything.
Table of Contents
Abstract  …………………………………………………………………………………i
Dedication  ………………………………………………………………………………ii
Acknowledgements………………………………………………………………………iii
Table of Contents………………………………………………………………………...iv
List of Tables and Figures………………………………………………………………..v
Chapter 1:  Background           1
1.1  Pyrimidine Biosynthesis and Aspartate Transcarbamoylase  ..……………..………..1
1.2  A Crystallographic and Computational Approach to Drug Design  ..……..………....6
1.3  Mutants of ATCase and the T to R Transition  ..……………………………………12
1.4  Project Objectives  .…………………………………………………………………14
Chapter 2:  Materials and Methods        15
2.1  Materials  ..………………………………………………………………………….15
2.2  Strains  ……………………………………………………………………………...15
2.3  Methods  ……………………………………………………………………………15
Chapter 3:  Results        18
3.1  Wet Lab Results  …………………………………………………………………...18
3.2  The Crystal Structure and Computational Results  ………………………………...20
Chapter 4:  Discussion        27
Chapter 5:  References 29
vList of Tables and Figures
Figure 1.1   The Pyrimidine Biosynthetic Pathway………………………………………2
Figure 1.2  Aspartate transcarbamoylase’s condensation of carbamoyl phosphate and L-
aspartate to N-carbamoyl-L-aspartate……………………………………...…1
Figure 1.3   Schematic of the ATCase holoenzyme………………………………………4
Figure 1.4 Quartenary changes of ATCase during the T to R transition………………..5
Figure 1.5   The two binding domains of the ATCase active site………………………..7
Figure 1.6 Bisubstrate analogue, PALA, bound across both active site domains………8
Figure 1.7   The asymmetric and C1-C2 unit of ATCase………………………………...9
Figure 1.8  Aspartic acid 236’s interaction at the C4-R1 interface…….……………….13
Figure 3.1   Photographs of the D236A crystals………………………………………...19
Table 3.1    Data Collection and Refinement Summary of the D236A Structure……….20
Figure 3.2   D236A active site with PAM ………………………………………………21
Figure 3.3   Backbone trace of T and R catalytic subunits……………………………...23
Figure 3.4 Aspartate docked into the D236A active site………………………………24
Figure 3.5   The hydrogen bonding interactions of PAM……………………………….25
CHAPTER 1:  INTRODUCTION
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1.1  Pyrimidine Biosynthesis and Aspartate Transcarbamoylase
Nucleic acids are blueprints for the design and function of every living thing on this
planet. Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) store and transfer
genetic information and serve as templates for protein synthesis in the organism. In order
for organisms to grow and survive, they must be able to manufacture new nucleoside
bases for the production of DNA and RNA. Without these important small molecules
organisms cannot subsist. Crippling the ability of a cell to generate these nucleotides
elucidates the crucial role of these polymeric nucleic acids on a cellular and organismal
level.
Two independent pathways serve to create nucleotides, one for purines and one for
pyrimidines. The pyrimidine biosynthetic pathway is illustrated in Figure 1.1. In a
healthy cell, the amounts of pyrimidines and purines are carefully balanced and regulated
by strict control over the rates of the biosynthetic pathways, allowing the cell to maintain
healthy ratios of the bases to one another (1). The pathways must be able to be up-
regulated when demand for specific nucleotides is high, like when the cell is dividing,
and down-regulated when there is an excess of given nucleotides. An early step in the
synthesis is an ideal control point, provided the temporary build up of substrates is
benign. In this manner, the cell can down regulate nucleotide production before
committed steps have been performed, leaving the basic molecular building blocks free
for other applications in the cell.
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Figure 1.2.  The condensation reaction of ATCase.
In Escherichia coli, the enzyme aspartate transcarbamoylase (ATCase) carries out the
committed step in the pyrimidine biosynthetic pathway. As shown in Figure 1.2, it
catalyzes the condensation of L-aspartate and carbamoyl phosphate (CP) to N-
carbamoyl-L-aspartate (CA) and inorganic phosphate (Pi) (2). This reaction occurs in an
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ordered fashion, with CP binding first followed by aspartate and CA leaving before
inorganic phosphate. It is an allosteric enzyme, and therefore, is a large, multi-subunit
complex. Specifically, it is a dodecamer (Mr = 310,000) consisting of six identical
regulatory chains organized into three dimers (R2, Mr = 34,000) and six identical catalytic
chains organized into two trimers (C3, Mr = 100,000). This quaternary stucture is
displayed schematically in Figure 1.3. The molecule has a three-fold axis of symmetry
and contains six active sites and six regulatory sites (3).
ATCase not only catalyzes the committed step in pyrimidine biosynthetic pathway, but
also regulates it. The formation of CA occurs early in the biosynthesis, and its only
metabolic fate is to be a precursor for pyrimidine nucleotides. The substrates of the
ATCase reaction, CP and aspartate, are not harmful to the cell at elevated concentrations
allowing for safe down regulation of the pathway which results in a temporary buildup of
the substrates (1). Allosteric enzymes, by definition, can exist in two states and undergo
an allosteric transition. The low activity state has a low affinity for its substrates and is
called the “tense,” or “T,” state. The enzyme’s high activity, high affinity conformation
is called the “relaxed,” or “R,” state. The allosteric transition , in addition to being
understood as an activity change, can also be understood as a change in quarternary
structure. The enzyme expands approximately 11Å along its three-fold axis with the
catalytic trimers rotating 12° relative to one another and the regulatory dimers rotating
15° (Figure 1.4) (4). In ATCase, this dual rate activity can be observed through kinetics
studies. An aspartate saturation curve at saturating concentrations of CP has a sigmoidal
shape which is reflective of the two distinct activity states of ATCase as opposed to a
typical Michaelis-Menten activity (3). The binding of aspartate in the presence of CP
causes the enzyme to shift to its high activity state in a concerted fashion according to the
Monod, Wyman and Changeux model (5).
Allosteric enzymes also have regulatory binding sites that are remote from the active sites
and moderate the activity shifts. In ATCase, these binding sites exist in the regulatory
dimers, with one site in each polypeptide chain. Its heterotrpic inhibitors, cytidine 5’-
triphosphate (CTP) (6) and uridine 5’-triphosphate (UTP), in the presence of CTP (7),
Kelly J Dusinberre
Figure 1.3. Schematic of the ATCase holoenzyme.  The large yellow spheres are
catalytic subunits and are organized into two trimer, an upper and a lower.  Only two of
the regulatory dimers are visible, but their relationship to the catalytic trimers can be
observed.  This image was created by Dr. Evan Kantrowitz.
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reduce the activity of ATCase by shifting the equilibrium of the enzyme toward its low
activity state. Adenosine 5’-triphosphate (ATP) acts as a heterotropic activator, shifting
the equilibrium of the enzyme toward the higher activity state of ATCase (8).
In cancerous tumors, cells proliferate unregulated. One way to stop the growth of tumors
may lie in limiting the ability of the cells to replicate themselves by reducing their ability
to create new nucleotides. Theoretically, this can be done by disabling the pyrimidine
biosynthetic pathway. One potent inhibitor, N-phosphonoacetyl-L-aspartate (PALA), has
been well characterized and tested in this capacity. A bi-substrate analogue, it binds 1000
times more tightly than CP, making it a very competitive inhibitor at very low
concentrations even though the binding is reversible. Upon the binding of a single PALA
molecule, the holoenzyme undergoes its allosteric transition, actually increasing in
activity until the other active sites are filled with PALA molecules. This change is
effected because PALA can bind across both the CP and aspartate domains in the active
site once it draws them together and forms the R-state active site (9). The two domains
are highlighted in Figure 1.5 and PALA binding across the two domains is shown in
Figure 1.6. Domain closure must occur for catalysis to occur or the substrates would not
be brought close enough together to react. Unfortunately due to the severity of the side
effects, PALA is not a good candidate for therapeutic use (10-13). Consequently, the
search for new inhibitors is ongoing.
1.2  A Crystallographic and Computational Approach to Drug Design
One current approach to the design of new inhibitors focuses on the docking of small
molecules into crystallographically determined models of the ATCase active site.
ATCase crystals can be grown for X-ray structure studies and it crystallizes in several
space groups, including the P321 space group. In this space group, the asymmetric unit
is two catalytic chains, one from the top trimer and one from the bottom (C1-C6), and the
regulatory dimer that is most closely associated with this catalytic pair (R1-R6) (14). In
examining x-ray crystallographic structures to explore ligand binding, this is a convenient
unit for analysis because there are two active sites, one representative of each catalytic
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trimer. A C1-C2 unit is also necessary to explore the active site of ATCase as the 80s
loop from an adjacent chain is necessary to complete the active site of any given catalytic
unit. These two different units are diagramed in Figure 1.7. As the active site is being
explored in this study, the C1-C2 unit will be focused on.
A Unix based program called AutoDock is used to dock the small molecules into crystal
structures. AutoDock allows the user to define a ligand, complete with charges and polar
hydrogens, and adjust Protein Data Bank files of protein crystal structures so that the
interactions between the two can be assessed. A grid for each type of atom is created for
a user-defined region of the protein that encompasses the proposed binding site. The
program can then assess electrostatic and steric interactions between the ligand and the
protein. Based on these calculations, it generates binding and docking energy estimates
for the given ligand in multiple binding orientations in the specified crystallographic
binding site. The lowest energy binding for the molecule is assumed to be its natural
docking position and these numbers are used to crudely compare the efficacy of small
molecules that have yet to be tested against the protein in vitro or in vivo (AutoDock
manual). In the case of ATCase, the grids are defined to include the active site so that the
binding of small molecule inhibitors can be assessed.
Both T- and R-state active site models are used for docking studies because the inhibition
of either state of the enzyme should be therapeutically viable. There are many ATCase
structures refined from crystals made under a variety of conditions. They are available
from the Protein Data Bank. One of the structures currently being used to do the small
molecule screens is ATCase with an unligated T active site (PDB code 1RAI) (15). The
T state form of ATCase has a unit cell with dimensions a = b = 122 Å, c = 142 Å in the
P321 space group (16). In this structure, the active site is very open with the aspartate and
CP domains separated from one another. The 80’s loop, which is a highly mobile string
of residues that moves into the active site of an adjacent catalytic chain in the R-state, is
not yet part of the active site when the enzyme is in the T-state (3, 17). The inhibitor
candidates docked into this T-state active site thus far have not been able to induce the
domain closure that PALA does and are too small to bridge both domains,
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which limits their potency. Due to this, the binding and docking energies calculated by
AutoDock are always lower for the T-state active state than the R-state.
Other T-state models are also available for study. To best assess substrate binding to the
CP site in the T-state enzyme, a structure of the enzyme ligated with it, could be used. A
recently solved structure in the Kantrowitz group shows that the binding of CP to
ATCase stabilizes the CP long enough for crystallization. While the binding of CP alone
to wild-type ATCase does not effect the T to R transition, small changes in the active site
do occur (18, 19), and this intermediate conformation could also be useful in the selection
of promising inhibitors. Another T-state model with products, CA and Pi, bound is also
of interest (20). For each of these structures, the ligands can be selectively removed from
the active sites of the protein model, and new small molecules can be docked into the
sites using AutoDock. These models could be used to predict the binding of new
inhibitors to the CP domain, or to identify which domain a novel inhibitor might prefer.
Kinetic and structural studies of ATCase with PALA bound have shown that the enzyme
is fully converted to its R conformation with a unit cell a = b = 122Å and c = 156Å (9,
21). Multiple structures of the enzyme with PALA have been solved, and all show a full,
closed active site (21, 22). One concern with the PALA structure, however, is that it is
unknown whether or not the binding PALA induces an artificial conformation of the
active site. The bridging carbon in PALA is not tetrahedral (9) as the true transition state
is predicted to be, and therefore there is currently no sure way to know how the active site
in the R conformation would look as the condensation reaction is being carried out. If the
PALA molecule is removed from the active site and aspartate and CP are both docked
into the protein structure, it is apparent that the two would not fit into the active site
simultaneously. Even if the model is representative of the active site during catalysis, the
structure of the enzyme before and after catalysis is still unknown. Logically, both
substrates must at some point coexist in the R-state active site before catalysis is carried
out. There may be an alternate R-state active site conformation that, while not very
different from the one PALA occupies, allows for the binding of both substrates
simultaneously, revealing the pre-catalytic form of the R-state active site.
Kelly J Dusinberre
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To help elucidate the active site conformation in the R-state, other substrate analogues
have been crystallized with ATCase. When ATCase is crystallized with both PAM and
malonate, the enzyme transitions and R-state crystals result. The active site, under these
conditions, is very similar to that of a PALA bound ATCase (18). A citrate and inorganic
phosphate bound enzyme also has an active site structurally similar to that of the PALA
enzyme (23). These structures do not yield significantly different active sites from the
PALA model and are therefore equivalent in value in docking studies and in
understanding catalysis. Both natural substrates cannot be docked concurrently into the
macromolecule in any of the currently available R-state structures. The only R-state
structures of ATCase available have both domains of the active site full with either two
different species or with PALA.
1.3  Mutants of ATCase and the T to R Transition
A great deal about the structure-function relationship in ATCase has been learned from
site-specific mutagenesis studies of the enzyme. Specific residues that are believed to be
important in various aspects of enzyme function are mutated, and kinetic and
crystallographic studies are then done on the mutants (24-26). Active site residue
interactions, regulatory binding site interactions and intersubunit interfaces have all been
interrupted to cause various activity changes to the enzyme.
Much of this type of work has to been done to explore how the T to R transition occurs
and what interactions stabilize each state. In the T-state, Asp-236 in the catalytic chain
interacts with Lys-143 of the regulatory chain in a C4-R1 manner (Figure 1.8). This is an
important T-state stabilizing interaction. When Asp-236 is mutated to an alanine residue
(D236A), the T-state is greatly destabilized allowing the T to R transition to occur much
more easily. The single amino acid change actually interrupts six interactions as there is
one in each catalytic chain. It has been previously shown that if three of these
interactions are left intact, while the enzyme is not in a normal T-state, it is in a T-like
state and can undergo the T to R allosteric transition (26). However, with all six
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interactions interrupted, the enzyme is no longer cooperative and has and increased
affinity for aspartate but maintains its full activity (26). When PALA is added to the
enzyme under saturating CP conditions, there is no activation unlike the result when the
same conditions applied to wild-type enzyme. The presence of CP alone can induce the
T to R transition in this mutant (26). If the enzyme transitions without both substrates or
both substrate analogues bound, this offers an opportunity for the crystallization of
ATCase in the R state with a partially empty active site.
1.4  Project Objectives
D236A crystallized with PAM offers the opportunity to look at an R-state ATCase
structure with a wild-type active site in which only one substrate domain is full. One of
the major aims of this thesis was to purify the D236A enzyme, determine conditions for
crystallization and solve the structure of the D236A enzyme in the presence of
phosphonoacetamide, an analog of CP. Examination of this structure should give insight
into the catalytic mechanism of ATCase as a partially full R-state active site has never
before been observed. The docking of substrates in this new active site may help to
elucidate the conformational changes that the enzyme undergoes in its allosteric
transition, as well as offering a more useful model for small molecule screens. In order to
obtain the most realistic, and therefore most useful, binding estimates from AutoDock, it
is imperative that a representative active site model be used for the docking studies. The
secondary aim, therefore, is to obtain an active site model that yields binding estimates
that more closely correlate with observed inhibition.
CHAPTER 2:  MATERIALS AND METHODS
Kelly J Dusinberre
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2.1 Materials
2-mercaptoethanol, agar, ammonium persulfate, Bis-Tris, calcium chloride, enzyme-
grade ammonium chloride, ethylenediaminetetraacetic acid disodium salt, ferrous sulfate,
glucose, L-aspartate, L-tryptophan, N-carbamyl-L-aspartate, polyethylene glycol 1450,
potassium phosphate monobasic, sodium chloride, sodium dodecyl sulfate, sodium
phosphate, thiamine, Tris, uracil, and zinc sulfate were purchased from Sigma Chemical
Company. Carbamoyl phosphate dilithium salt was also obtained from Sigma, but was
recrystallized from 50% (v/v) ethanol and stored at -20°C. Fisher Scientific provided
2,4-butanedione monoximine, antipyrine, casamino acids, magnesium sulfates, tryptone
and yeast extracts. TEMED from Bio-Rad and electrophoresis grade acrylamide from
ICN Biomedicals were used in SDS-PAGE gels. Q-Sepharose Fast Flow resin was
purchased from Pharmacia. Dialysis tubing, MWCO 3500, was purchased from
BioDesign Inc. of New York.
2.2  Strains
The E. coli strain EK1104 (F- ara, thi, (pro-lac), pyrB, pyrF±, rpsL) containing
pEK114 was used to overexpress the D236A enzyme under limiting growth conditions as
previously described (27).
2.3  Methods
Overexpression and Purification of the D236A Aspartate Transcarbamoylase Mutant.
The mutant ATCase was expressed in the strain EK1104 transformed with plasmid
pEK114. E. coli were cultured at 37°C for 24 hours in M9 media (28) with agitation and
the cells were then resuspended in 0.1 M Tris, pH 9.2 and lysed by sonication.   Two 65%
ammonium sulfate precipitations were performed, as well as a precipitation at pH 5.8 in
0.01M potassium phosphate buffer. A Q-Sepharose Fast Flow column was used for ion-
exchange purification (29). The purity of the enzyme was assessed by nondenaturing
polyacrylamide gel electrophoresis (30, 31).
Kelly J Dusinberre
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Concentration of and Determination of the Protein Concentration. The Amicon pressure
concentration system was utilized to concentrate the purified protein to approximately 12
mg/mL. The concentration was determined by absorbance measurement at 280 nm using
the known extinction coefficient of wild-type enzyme, 0.59 cm2•mg-1 (32). It was
assumed that the single mutation would not significantly alter the extinction coefficient
from that of wild-type.
Aspartate Transcarbamoylase Colorimetric Assay. An aspartate saturation curve of the
purified D236A protein was performed in duplicate at 25°C to affirm the identity of the
protein and review its activity profile. Enzyme concentration was 0.03 µg/mL, buffer
solution was 0.05 M Tris acetate at pH 8.3, and the CP concentration was 4.8 mM. The
development and processing of the assay were done according to previously published
procedures (33). Nonlinear regression was used to fit the data to the theoretical
BHMINN equation, an extension of the Hill equation that takes substrate inhibition into
account (34).
Crystallization of the D236A Enzyme and Freezing of Crystals. Initially, D236A was
crystallized by the hanging drop method under a variety of conditions: the Tris
concentrations ranged between 2.5 and 25 mM, PEG 1450 concentrations ranged from 14
to 19% and the EDTA concentration was 10 mM. D236A was also crystallized by
microdialysis in 5 mM PAM, 50 mM maleic acid and 3 mM sodium azide solution. 60 µl
aliquots of protein previously dialyzed against 40 mM potassium phosphate, 0.2 mM
EDTA, and 2 mM 2-mercaptoethanol was added to each 50l microdialysis well.
Crystals grew to average dimensions of 0.5 x 0.5 x 0.1 mm in approximately 7 days. The
crystals were frozen in liquid nitrogen after an ~1 minute soak in 30% 2-methylpentadiol
in crystallization buffer.  This solution acts as a cryoprotectant.
X-ray data collection and processing. The data for the structure in the D236A ATCase
were collected using a Rigaku R-axis IV++ detector while X-rays were generated using a
Rigaku RU-200 rotating-anode generator operating at 50 kV and 100 mA at the
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Crystallographic Facility in the Chemistry Department of Boston College. The diffraction
data were integrated, scaled and averaged using d*TREK (35).
Structural Refinement. Before beginning refinement, all water molecule and ligands
were removed from the structure. The initial model used for the D236A refinement was a
R-state model that had been previously published (PDB code: 8AT1(36)). The
refinement was carried out using CNS (37). Initial rigid body, simulated annealing,
minimization, and B-factor refinement were completed. The initial maps showed a
disordered N terminus, so the first 7 amino acids were removed and then manually rebuilt
in XtalView (38). Using a technique of overlaying the D236A model on R-state
structures that had already been solved (PDB codes 8AT1(36) and PDB code 1D09(21)),
corrections were made to the structure. The placement of PAM in the active site was
done manually after the rebuilding of the 80’s and 240’s loops and was checked by
simulated annealing maps calculated in CNS (37). Waters were added to the structure
using CNS and XtalView on the basis of Fo–Fc electron density maps at or above the 2.5
 level, and were checked and retained only when they could be justified by hydrogen
bonds.  The model was checked using the program PROCHECK (39).
Graphics.  The figures were prepared with POVScript+ (40) and CHIMERA (41).
Docking Studies. Active site grids of the ATCase R-state active site were made for the
D236A with the PAM molecule in the active site in AutoDock. These served to compile
the simulated environment for the docking studies. Aspartate was docked into the refined
crystal structure with PAM in the active site. The lowest energy conformation was
selected for evaluation. Additionally, the PALA molecule was removed from the 1D09
structure (21) and both ligands, PAM and CP, were docked into the active site.
CHAPTER 3:  RESULTS
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3.1  Experimental Results
The D236A mutant was successfully overexpressed in E. coli using the EK1104 strain
and plasmid pEK114. The culture yielded a red-pink pellet and the color persisted
through much of the purification. Nondenaturing PAGE gel showed a strong, clean band
corresponding to ATCase holoenzyme, and the absorbance at 280nm indicated that
approximately 18 milligrams of protein were purified from the two liter culture. This
yield is lower than expected, but a later culture gave higher yields. This culture may not
have been allowed to grow long enough. Comparison of colorimetric assay results with
the literature characterization of the mutant confirmed its identity. The maximal velocity
(Vmax) was approximately 27 mmol•h-1•mg-1, the expected lack of cooperativity and
substrate inhibition were observed. The nonstandard coloration of the culture did not
impact the protein’s activity. The protein was concentrated to 13 mg/mL in an Amicon
pressure concentrator. Crystals of this protein were grown in less than a week by the
hanging drop method under a variety of crystallization conditions, but the highest
resolution of X-ray diffraction achieved was 4.0Å. Photographs of the crystals are
presented in Figure 3.1. Even with this low resolution, the space group was identified as
P321 and it was apparent that the enzyme had indeed transitioned from the T state to the
R state in the presence of PAM alone.
While crystals were relatively easily obtained by the hanging drop method, microdialysis
crystallization was carried out in an attempt to obtain crystals that diffracted better. The
same protein used for the hanging drop crystals was used for microdialysis crystallization
at pH 5.8. Only one crystal grew, and because the protein by this time was nearly a
month old a new culture was made. The new culture had the same red-pink color, but
also purified satisfactorily and had characteristic activity. The protein was concentrated
to 12 mg/mL and crystals were grown at pH 5.7 by microdialysis. A number of viable
crystals were obtained despite some precipitation of the protein in the microdialysis
buttons. One crystal was over 1 mm long; it was broken, and a 0.4 mm by 0.6 mm
fragment was frozen and mounted. Data were collected at a detector distance of 200 mm.
The crystal diffracted to 2.9Å, which allowed for clear determination of global quaternary
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structure as well as visualization of the active site and the position and orientation of the
PAM molecule.
3.2 The Crystal Structure and Computational Results
Kimberly Stieglitz generously refined the data set obtained from the microdialysis
crystals. Table 3.1 gives an abbreviated summary of the details of data processing and
refinement statistics for the structure. The solved crystal structure had a single PAM
molecule in the CP domain of the active site of C1, with the aspartate domain left empty
(Figure 3.2).  The C6 subunit also had PAM present but at a lower occupancy level.
Table 3.1
Data collection and Refinement Summary of the D236A  Structure
Data collection D236A
Space Group P321
dmin (Å) 2.90
Unit cell (Å)     a = b = 120.452,
       c = 155.242
Refinement
Resolution range (Å) 30.0-2.90
Sigma cutoff (s) 2.0
Working R-factor
Beginning 0.420
End 0.2146
Free R-factor
Beginning 0.450
End 0.291
Various structures were downloaded from the Protein Data Bank. For the comparison of
quaternary structure, a T-state model with regulator CTP (PDB code: 1RAI (15)) was
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examined. This showed that the D236A enzyme had undergone the changes to transition
globally from T to R. An R state model with PALA in the active site (PDB code: 1D09
(21)), and an R state structure with PAM and malonate crystallized in the active site
(PDB code: 3AT1 (36)) were used for active site comparisons. All of the characteristic
residue movements associated with the T to R transition had occurred in the D236A
crystal, including the drawing in of several residues in the 80s loop of the adjacent
catalytic chain. The rearrangement of the loops that occurs as the enzyme transitions to R
is illustrated in Figure 3.3.
The active site model with PAM in it was used to design grids in AutoDock. These grids,
along with a ligand file, were used to predict where the aspartate molecule was most
likely to bind in this R state active site in the presence of PAM. The aspartate molecule
docked into the aspartate domain of the active site as predicted.  The molecule produced a
binding energy of –8.26 kcal/mole, and a docking energy of –9.19 kcal/mole. The
docked position and orientation are presented in Figure 3.4. More importantly, all of the
most favorable docking energies showed the aspartate docked in the expected orientation,
but positioned too far from the CP analogue for catalysis to occur. The approximate
distance between the attacking nitrogen of aspartate and the carbon of PAM or CP is
4.41Å. In the structure containing both PAM and malonate, the two molecules bound
into the active site are much closer together because there is no amino group on the
malonate. This eliminates the inability of the two groups to achieve catalytic proximity
to one another. Therefore, the active site can close itself further than would be possible
were both substrates bound in vivo, prior to catalysis.
To best compare which interactions between the active site residues and the ligands were
intact in each model, Ligplot and Chimera were used to predict hydrogen-bonding
interactions between the PAM and the active site residues in the D236A structure. These
hydrogen-bonding interactions were compared with the known interactions of substrates
or substrate analogues and their respective active sites. The majority of hydrogen
bonding interactions were common to all of the structures examined despite their
different ligands and the different relative distances of the ligands to one another. The
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hydrogen bonding interactions with PAM are presented in Figure 3.5. Though there are
differences between the structures, all the major interactions are intact and all of the
major loop rearrangements associated with the T to R transition have occurred in the
D236A structure.
Additionally, there is a novel hydrogen bonding interaction in the D236A structure that
appears significant. Arg296 coordinates to PAM with a hydrogen bonding distance of
approximately 3.17Å, well with in the 2.5-3.5Å average hydrogen bonding distance. In
1D09 this same interaction is 5.80Å long, much too long to be participating in the
binding of PALA and in 2AT1 it is nearly as long at 5.76Å. The shift in this residue is
very clear in structural overlays.  The probing of this model is ongoing.
CHAPTER 4:  DISCUSSION
Kelly J Dusinberre
27
Understanding an enzyme’s method of catalysis is vital in manipulating its behavior. The
purpose of this project, therefore, is two fold. Firstly, it was hoped that the D236A
mutant would crystallize in an R-state conformation, but with a partially empty active
site. Indeed, the enzyme does globally transition to the R-state with only one of the
active site domains occupied. The active site of this structure is not only less full, but
also appears to be more open than that of the previously solved R-state structures. This
difference becomes significantly more striking when the second substrate, aspartate is
computationally docked. That it docked correctly can be stated with confidence because
so many of the standard hydrogen bonding interactions observed in other R-state
structures are present when aspartate is placed in the active site in the position and
orientation suggested by AutoDock. What was unexpected was the distance between the
reacting sites on the substrates. A normal catalytic distance is approximately 3-3.5 Å, but
the observed distance is 4.41 Å. This distance is much too great for catalysis even if
some docking uncertainty is taken into account. Other physical measurements that are
not presented here also support the open domain theory.
This result is exciting because it is a view of the ATCase active site as it may exist just
before and just after catalysis. As previously mentioned, the reaction of ATCase is
ordered. The first substrate to bind is CP. Aspartate binds second, and upon its binding,
the wild-type enzyme transitions from T to R. After catalysis is completed, the products
are also released in an ordered manner with carbamoyl aspartate leaving first, followed
by inorganic phosphate. When the products leave, the enzyme does not necessarily shift
back to its R-state. In fact, most of the time other active sites will be full or partially full,
and therefore, the next CP molecule to enter the active site in question may bind into an
active site that is already in the R-state. This is the moment that the D236A crystals with
PAM have captured. Catalysis has already “occurred,” and now new substrate molecules
are navigating an R-state active site. The CP molecule has bound and these crystals show
the environment into which the next asparate molecule would be introduced. The
domains being more open suggests an answer to how the substrates and products could
exchange without the enzyme undergoing the T to R transition every time one of the
active sites performs its reaction.
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Another tantalizing active site characteristic is the hydrogen-bonding of Arginine 296 to
the PAM molecule. This residue has not been previously observed in substrate binding,
but clearly is involved here. The role of this residue is not clear. Does it play a role in
guiding or positioning the substrate before aspartate binds? Does it play a vital, but
previously concealed role in shuttling substrates, facilitating catalysis and improving the
turnover rate of ATCase? Mutagenesis and kinetic studies may be able to partially
address these questions.
The second purpose of this project was to optimize computational small molecule
screens. The main challenge in designing small molecule inhibitors to enzymes of interest
lies in determining the characteristics of the binding environment. If it can be accurately
modeled, intelligent design can begin to replace large-scale screens in the laboratory
which are time and resource consuming. Additionally, databases containing millions of
compounds can be screened by computational methods. The interactions between the
small molecule and the local environment in its binding location can be estimated. This
system, however elegant in theory, must be carefully implemented. If the binding site
does not accurately reflect an in vivo condition, the correlation between predicted binding
and true binding will be compromised. In the case of ATCase, designing inhibitors offers
a unique challenge because of its two active site conformations.
The inhibition of ATCase, as previously stated, is of interest because of its possible
therapeutic value in fighting cancer. Currently, screens are being done using both T- and
R-state active sites but the correlation between the estimated binding energies and in vitro
inhibition is not optimal. This novel active site conformation may be a more useful tool
for the docking studies. The active site does not have an artificial conformation induced
by PALA binding and may, therefore, be more representative of what occurs during, or
just before, catalysis. Once the structure is finalized, this active site will be compared
with the standard T- and R-state active sites to assess its utility in docking studies and
small molecule screens.
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